Zenas BioPharma, Inc. ZBIO
26.95
(0.55)
(2.00%)
as of 25 Sep
- Market cap
- $1.8B
- P/E
- 0.0×
Follow ZBIO
Insider Buys
alert about insiders buying in the last 12 month
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (0.92) | (2.80) | (30.99) |
P/B ratio |
— | 0.00 | 0.35 | 6.71 |
Price to Tangible BV |
— | 0.00 | 0.35 | 6.71 |
EV/Sales |
— | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
— | 0.00 | 1.44 | 0.00 |
EV/Operating CF |
— | 0.48 | 2.03 | (7.89) |
EV/FCF |
— | 0.48 | 2.03 | (7.89) |
Quick Ratio |
2.59 | 2.44 | 6.12 | 5.48 |
Current Ratio |
2.64 | 2.57 | 6.21 | 5.61 |
Net Debt/EBITDA |
0.88 | 0.99 | 2.14 | 0.69 |
Debt/Assets |
0.00% | 29.77% | 0.00% | 20.50% |
Debt/Equity |
0.00 | (0.09) | 0.00 | 0.32 |
Asset Turnover |
— | 0.70 | 0.02 | 0.03 |
Operating CF/Net income |
0.55 | 0.82 | 0.76 | 0.46 |
Capex/Depreciation |
(2.54) | (0.15) | (0.96) | (0.32) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 17.76% | (361.99%) | (136.22%) | |
| 0.00% | (52.01%) | (71.66%) | (100.25%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(279.15%) | (101.05%) | (52.54%) | (130.91%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 120.07% | 2,782.78% | 1,680.63% |
Selling, General and Administrative Expense of Revenue |
0.00% | 34.23% | 594.98% | 533.22% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 6.99% | 216.42% | 263.47% |
Graham Net Nets |
— | 2.41 | 2.76 | 0.13 |
Graham Number |
— | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (141.80%) | (145.29%) | (21.51%) |
Free Cash Flow Yield |
— | (284.31%) | (110.83%) | (10.61%) |
Revenue per Share |
0.00 | 32.66 | 0.38 | 0.22 |
Operating CF per Share |
(44.00) | (19.94) | (9.07) | (3.85) |
Capex per Share |
(0.13) | (0.01) | (0.01) | 0.00 |
Free Cash Flow per Share |
(44.14) | (19.95) | (9.08) | (3.85) |
Cash per Share |
45.05 | 37.14 | 26.58 | 7.67 |
Shareholders Equity per Share |
(128.88) | (147.43) | 23.67 | 5.41 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(128.88) | (147.43) | 23.67 | 5.41 |
Free Cash Flow |
(65.85) | (30.55) | (119.80) | (172.35) |
Working Capital |
42.48 | 36.55 | 298.63 | 288.52 |
Capital Expenditures |
(0.20) | (0.02) | (0.13) | (0.02) |
Net Current Asset Value |
(198.42) | (234.10) | 298.41 | 209.68 |
EV/EBIT |
— | 0.00 | 1.48 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.00 |
Net Profit Margin |
0.00% | (74.25%) | (3,139.76%) | (3,777.37%) |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.31 | 0.59 | 0.74 | 1.65 |
Cash ROIC |
52.69% | 20.68% | (18.07%) | (25.96%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 5.61 | 11.27 | 12.12 |
Average Assets |
— | 71.38 | 219.07 | 376.80 |
Average Common Equity |
— | (209.00) | 43.37 | 277.30 |
Columns are period end dates